PBLS Company Profile and Key Details

Parabilis Medicines, Inc. has 121.95 million shares outstanding. The public float is 82.07 million shares, elevated short interest at 4.24% of float. This equals 5.12 million shares. The short ratio is 11.48 days. Institutional investors hold 59.56% of the float. Insiders own 3.78%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Average 10-day trading volume of 1.70 million shares is significantly above the 3-month average of 602.95 thousand, indicating heightened recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $40.00. The high target offers 7.84% upside. The low target suggests -4.15% downside. The mean target is $41.67. This offers -0.14% upside. Parabilis Medicines, Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by 1306.06%.

Our AI price prediction model suggests that Parabilis Medicines, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.66%, with price expected at $37.28 by October 02, 2026, within a range of $36.17 to $38.47 3-Month Outlook: Projected rise of 19.43%, reaching $49.84 by December 17, 2026, with a range of $49.62 to $50.09. 1-Year Outlook: Projected gain of 178.65%, with price at $116.28 by September 17, 2027, within a range of $115.98 to $116.49.

Parabilis Medicines, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$15.32. This means the shares are trading below this model’s fair value.

Valuation shows Parabilis Medicines, Inc. trading at a premium to the broader market with a P/E of -1.12. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $41.67, suggesting -0.14% downside. Our AI forecast model points to short-term weakness (-10.66% over two weeks), a medium-term rise (19.43% over three months), and a longer-term gain (178.65% over one year), with expected trading ranges indicating moderate volatility.

Parabilis Medicines, Inc. (NASDAQ:PBLS) closed at $41.73 USD, gaining $0.85 (2.08%) from the previous close of $40.88. The stock is currently within 5% of its 52-week high $24.51 and $42.34. With a market capitalization of about $4.86 billion, Parabilis Medicines, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 467.05 thousand shares, trading with heavier-than-usual volume. Headquartered in Cambridge, MA, Parabilis Medicines, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mathai Mammen, the company employs approximately 145 people and listed since June 10, 2026. Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company.

Parabilis Medicines, Inc. trades at a P/E ratio of -1.12, slightly below the S&P 500 average, with a price-to-sales ratio of 32657.77 and a price-to-book ratio of 1.14 suggesting the stock is closer to book value. The P/FCF stands at -89.83, also below market averages.